EUVIMEDOpdag EUVIMED
Crossref

Safety of biologics in severe asthmatic patients with SARS‐CoV‐2 infection: A prospective study

Sara Manti iD, Alessandro Giallongo iD, Giulia Pecora, Giuseppe F Parisi iD, Maria Papale, Enza Mulè, Donatella Aloisio, Novella Rotolo, Salvatore Leonardi

Pediatric Pulmonology · 2023

DOI: 10.1002/ppul.26298 ↗

At a glance

Journal article in Pediatric Pulmonology, 2023. Written by Sara Manti and 8 co-authors. Institution: Pediatric Respiratory Unit, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy. Major MEDLINE topics: COVID-19, Asthma, Biological Products. Cited 4 times so far (Crossref); 36 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Asthma guidelines have recommended continuing treatment with biologics during coronavirus disease 2019 (COVID‐19) pandemic. However, a continuation of treatment with biologics in patients with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been little investigated.

Objective

To assess the safety of biologics in patients with SARS‐CoV‐2 infection.

Methods

A pilot, monocentric, prospective study. Patients aged 6 years old and older with severe asthma on treatment with biologics and confirmed SARS‐CoV‐2 infection were enrolled. Patients were followed‐up with periodic calls at different time points up to 3 months to detect any adverse effect and its relationship with biologic treatment according to the Naranjo Adverse Probability Scale (NAPS). The severity of SARS‐CoV‐2 infection and clinical outcome were also assessed.

Results

Overall, we included 21 patients (10 on therapy with omalizumab, 9 with dupilumab, and 2 with mepolizumab). Only a patient‐reported two local adverse events. No other adverse event was reported. Twenty out of 21 patients had a mild COVID‐19 course, and no adverse outcome was observed.

Conclusion

We showed that the scheduled dose of the biologic therapy can be administered safely on time in patients with SARS‐CoV‐2 infection, as the treatment did not result in adverse events or outcomes.

Subjects

MeSH terms (MEDLINE)

COVID-19AsthmaBiological ProductsHumansChildSARS-CoV-2Prospective Studies

Author keywords

COVID-19asthmadupilumabmepolizumabmonoclonal antibodiesomalizumabsafety

Substances

Biological Products

Authors and institutions

  • Pediatric Respiratory Unit, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
  • Department of Human Pathology of Adult and Childhood Gaetano Barresi, Pediatric Unit, University of Messina, Messina, Italy.
  • Pediaric Unit, Maggiore Hospital, Modica, Italy.

ORCID profiles: Sara Manti, Alessandro Giallongo, Giuseppe F Parisi

Cite

APA

Manti, S., Giallongo, A., Pecora, G., Parisi, G. F., Papale, M., Mulè, E., Aloisio, D., Rotolo, N., & Leonardi, S. (2023). Safety of biologics in severe asthmatic patients with SARS‐CoV‐2 infection: A prospective study. Pediatric Pulmonology. https://doi.org/10.1002/ppul.26298

Vancouver

Manti S, Giallongo A, Pecora G, Parisi GF, Papale M, Mulè E, et al. Safety of biologics in severe asthmatic patients with SARS‐CoV‐2 infection: A prospective study. Pediatric Pulmonology. 2023. doi:10.1002/ppul.26298

BibTeX
@article{Manti2023,
  author = {Manti, Sara and Giallongo, Alessandro and Pecora, Giulia and Parisi, Giuseppe F and Papale, Maria and Mulè, Enza and Aloisio, Donatella and Rotolo, Novella and Leonardi, Salvatore},
  title = {Safety of biologics in severe asthmatic patients with SARS‐CoV‐2 infection: A prospective study},
  journal = {Pediatric Pulmonology},
  year = {2023},
  doi = {10.1002/ppul.26298}
}
Start for free →